ACTIVE_NOT_RECRUITING

ivWatch in Prevention of Extravasation of Vesicants in an Oncology Setting

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This study aims to determine the feasibility of using the ivWatch (registered trademark) device to determine if there is an infiltration at the site of a peripheral intravenous (PIV) catheter. An infiltration is when the IV fluid leaks out of a vein and into the surrounding tissue. If medication starts leaking outside the vein, it can cause damage to the surrounding tissue. Using the ivWatch device may identify leaking fluid before the nurse is able to visually observe the signs or symptoms of the leaking fluid.

Official Title

Feasibility Study for ivWatch® in Prevention of Extravasation of Vesicants in an Oncology Setting

Quick Facts

Study Start:2023-05-17
Study Completion:2026-11-17
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT06758011

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 95 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients requiring a peripheral IV for infusion of vesicant or vesicant-like agents (chemotherapy, other vesicant medications).
  2. * PIV must be inserted
  3. * Participant (or legal representative) must understand the nature of this study and verbally consent with the Research Study Information Sheet prior to receiving any study related procedure
  1. * Patients who are not getting a vesicant, irritant or vesicant like fluid infused.
  2. * Patients who are bruised, scarred, or tattooed in the area of the PIV.
  3. * Patients with skin integrity issues at the site of the PIV.
  4. * Patients who are on "light precautions."
  5. * Not for use in power injectors.
  6. * Not for use on mediports, implanted ports, IVAD, central lines, PICC lines.
  7. * Patients without a cancer diagnosis.

Contacts and Locations

Study Locations (Sites)

Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263
United States

Collaborators and Investigators

Sponsor: Roswell Park Cancer Institute

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-05-17
Study Completion Date2026-11-17

Study Record Updates

Study Start Date2023-05-17
Study Completion Date2026-11-17

Terms related to this study

Additional Relevant MeSH Terms

  • Oncology
  • Extravasation